Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

This study will evaluate whether adjuvant intravesical chemotherapy can be safely omitted under active surveillance after complete transurethral resection in selected patients with EAU intermediate-risk non-muscle-invasive bladder cancer. Patients with intermediate-risk non-muscle-invasive bladder cancer are commonly treated with transurethral resection followed by adjuvant intravesical chemotherapy to reduce the risk of recurrence. However, not all patients may derive the same benefit from additional intravesical treatment. Some tumors may have a low-shedding phenotype, meaning that they sho

Trial Details

NCT ID
NCT07749924
Phase
NA
Sponsor
Tianjin Medical University Second Hospital
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Active Surveillance
  • Adjuvant Intravesical Chemotherapy
Locations (sample)
  • Daqing, China|46.58333,125
  • Nanchang, China|28.68396,115.85306
  • Tianjin, China|39.14222,117.17667
  • Tianjin, China|39.14222,117.17667
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Age ≥18 years.
  • Histologically confirmed urothelial carcinoma of the urinary bladder, including tumors with divergent differentiation, provided that the urothelial…
  • Non-muscle-invasive bladder cancer classified as intermediate-risk according to the 2021 European Association of Urology (EAU) NMIBC prognostic ris…
  • Complete transurethral resection of all visible bladder tumors performed within 6 weeks before randomization, with no macroscopically visible resid…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →